Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 19, 2025
Join us in celebrating milestone moments from Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column publishes regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
Every step entrepreneurs take amid waves of technology and innovation deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower founders, and we invite you to join us in marking the milestone moments of our portfolio companies.
Funding News
01/
AusperBio Closes $50 Million Series B+ Round Qiming Venture Partners Continues Investment
AusperBio, a Qiming Venture Partners portfolio company, recently announced the completion of a $50 million Series B+ financing round. Qiming Venture Partners participated in the Series A round and has continued to invest through the Series B and B+ rounds.
This round follows AusperBio's Series B financing completed in December 2024, demonstrating investors' strong confidence in the company's leading product candidates, proprietary technology platform, and strategic direction. The proceeds will primarily fund continued clinical development of its innovative antisense oligonucleotide drug AHB-137 for functional cure of chronic hepatitis B (CHB), including planned Phase 2 clinical trials outside mainland China. The capital will also expand commercial manufacturing partnerships and advance pipeline expansion to support AusperBio's long-term growth.
02/
TicenoBio Raises Over 200 Million Yuan in Series C Qiming Venture Partners Co-Leads
TicenoBio, a Qiming Venture Partners portfolio company, announced the completion of a Series C financing round exceeding 200 million yuan. The round was co-led by existing shareholder Qiming Venture Partners.
The funds will focus on advancing the company's core pipeline: Phase 3 trials and subsequent commercial preparation for LP-003, a next-generation anti-IgE antibody, as well as Phase 2 development across multiple indications for LP-005, a first-in-class dual-function complement antibody — further strengthening TicenoBio's innovation edge in allergy and complement-mediated diseases.
LP-003 is the most advanced anti-IgE antibody in development globally. It has entered Phase 3 trials for allergic rhinitis, with a New Drug Application/Biologics License Application (NDA/BLA) expected in early 2026. Phase 3 trials for a second indication, chronic spontaneous urticaria, will launch in 2026. Phase 2 trials for additional indications including allergic asthma and food allergy are also underway, with continued expansion of the product's commercial potential.
LP-005 is a first-in-class dual-function antibody fusion protein that simultaneously inhibits all three complement pathways. It has demonstrated significant efficacy in Phase 2 trials for paroxysmal nocturnal hemoglobinuria (PNH). In 2025, clinical studies will initiate for complement-mediated kidney diseases (including IgA nephropathy and C3 glomerulopathy) and other conditions. With its innovative "one drug, multiple targets" mechanism, LP-005 holds promise to fill therapeutic gaps across multiple unmet clinical needs.
Major Partnerships
01/
DeepWay Signs Distribution Agreement with Australian Strategic Partner
Recently, DeepWay, a Qiming Venture Partners portfolio company, formally signed a distribution agreement with an Australian strategic partner and secured its first batch of orders. This partnership marks DeepWay's fourth country-level market deployment in the Asia-Pacific region, following Singapore, Thailand, and Malaysia — another major breakthrough in its global expansion strategy.
DeepWay will provide customized product solutions and localized service networks, delivering full-lifecycle support to partners and facilitating Australia's green freight transformation.
02/
Mofan Power Partners with National University of Singapore Hydrogen Innovation Research Center to Develop Next-Generation Ammonia Cracking Technology
Recently, Mofan Power, a Qiming Venture Partners portfolio company, formally signed a contract with the National University of Singapore Hydrogen Innovation Research Center to jointly develop next-generation ammonia cracking technology suitable for gas turbine applications. This technology will enhance the independence and stability of fuel supply systems for ammonia-powered gas turbines, further streamlining the "electricity-ammonia-electricity" cycle.
The partners plan to validate the advanced process at Mofan Power's pan-hydrogen gas turbine testing facility in Chifeng, Inner Mongolia, China, and expect ammonia power generation products equipped with this technology to enter the Singapore market first for green ammonia power generation demonstration applications.
03/
Superhexa's Jiehuan Brand Forms Strategic Partnership with Beijing Daming Optical
Recently, Superhexa, a Qiming Venture Partners portfolio company, announced that its smart glasses brand Jiehuan has formed a strategic partnership with Beijing Daming Optical. The two parties will collaborate deeply across product promotion, offline services, and scenario co-creation to jointly develop a new consumer category integrating vision correction with intelligent experiences.
The partnership will also launch the world's first "Jiehuan × Daming Smart Sound Field" intelligent experience zone, showcasing the application value of AI-powered audio glasses across office, commuting, learning, and sports scenarios through immersive "being there" interactive experiences — comprehensively elevating user awareness and engagement with smart glasses.
04/
Ark Biosciences Deepens Strategic Partnership with Partex to Advance Global Development of Novel ATR Inhibitor AK0658
Recently, Ark Biosciences, a Qiming Venture Partners portfolio company, announced a strategic partnership and follow-on agreement with Partex, a leader in AI-driven pharmaceutical innovation, to jointly develop and out-license AK0658, a preclinical-stage ATR inhibitor with best-in-class potential. This collaboration marks the second partnership between the two companies, following their earlier collaboration on the autotaxin inhibitor AK0707.
As a next-generation preclinical-stage ATR inhibitor, AK0658 demonstrates superior selectivity, optimized pharmacokinetic properties, and enhanced in vivo efficacy compared to Berzosertib, the current frontrunner in development. The compound shows significant therapeutic potential across multiple cancer indications driven by DNA damage response (DDR) pathway abnormalities.
05/
BiTree Bio Reaches Strategic Partnership with ANPEL Laboratory
BiTree Bio, a Qiming Venture Partners portfolio company, has formally signed a strategic partnership agreement with ANPEL Laboratory, a benchmark enterprise in scientific services. The two parties will collaborate deeply in technology R&D, product cooperation, and market expansion to jointly advance the industrialization of mass spectrometry technology in scientific research.
Going forward, both sides will establish a senior-level mutual visit mechanism with regular exchanges to ensure effective implementation of the partnership strategy. They will also conduct broad technical cooperation and knowledge sharing, integrating their technological resources to tackle industry challenges, drive innovation in biotechnology, expand brand influence, and open up broader market opportunities.
R&D Progress
01/
Insilico Medicine Publishes AI-Driven Research on Next-Generation ENPP1 Inhibitor in Nature Communications
Recently, Insilico Medicine, a Qiming Venture Partners portfolio company, published a breakthrough study in Nature Communications focusing on the ENPP1 target to develop small-molecule inhibitors capable of modulating the STING pathway and enhancing tumor immunity. In the paper, the research team used a cutting-edge generative AI platform and its integrated workflow to identify and validate ENPP1's role as a critical immune checkpoint across multiple solid tumors, thereby facilitating the development of ISM5939, a highly specific oral ENPP1 inhibitor for tumor immunotherapy.
Notably, this marks Insilico Medicine's third Nature sub-journal publication in 2025 themed on AI-driven drug discovery practice, and the fourth Nature sub-journal paper based on its AI-powered novel drug discovery pipeline.
02/
Abbisko Pharma's Irpagratinib Receives Breakthrough Therapy Designation in China for Hepatocellular Carcinoma
Recently, Abbisko Pharma (02256.HK), a Qiming Venture Partners portfolio company, announced that its self-developed highly selective small-molecule FGFR4 inhibitor irpagratinib (ABSK011) has received Breakthrough Therapy Designation from the Center for Drug Evaluation, NMPA (CDE) for the treatment of hepatocellular carcinoma (HCC). Irpagratinib is the first drug to employ targeted molecular biomarkers for precision treatment of HCC.
Currently, patients with advanced or unresectable HCC lack effective subsequent treatment options after receiving ICI and mTKI therapies. Patients with FGF19 overexpression often have poorer prognoses, creating an urgent need for new treatment alternatives. The Breakthrough Therapy Designation will help accelerate irpagratinib's subsequent regulatory filing and approval process, bringing new hope to a large population of patients with unmet medical needs. Abbisko Pharma's pivotal registrational clinical study for irpagratinib has officially launched at Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, and Nanjing Tianyinshan Hospital.
03/
Cure Genetics Publishes AAV Therapy Research in Tumor Immunotherapy in Molecular Therapy Oncology
Recently, leveraging tumor-targeted AAV vectors, Cure Genetics, a Qiming Venture Partners portfolio company, published a study in Molecular Therapy Oncology on the application of AAV therapy in tumor immunotherapy (project code: CGC-008). Using its self-developed targeted AAV delivery technology (targeted viral particles), the company precisely delivers interleukin-12 to the tumor microenvironment to develop innovative therapies for ovarian and endometrial cancers, exploring the feasibility of AAV gene therapy in large indications.
The CGC-008 product offers three key advantages: its innovative tAAV9 vector demonstrates strong tumor cell preference in both in vivo tissue distribution and cellular infection, effectively preventing toxicity from liver off-target effects; after infecting tumor cells, tAAV9 enables IL-12 expressed by tumor cells to locally activate TME immune cells and enhance immune cell infiltration into solid tumors, reducing the risk of IL-12 circulating in peripheral blood; as tumors are suppressed, IL-12-expressing tumor cells gradually decrease, thereby lowering IL-12 expression — this downregulation mechanism provides an additional safety safeguard.
04/
Amoy Diagnostics Contributes to Study on First-Line Combination Therapy for Extensive-Stage Small Cell Lung Cancer Published in Nature Sub-Journal
Recently, a team led by Professor Chunxia Su from the Department of Oncology at Shanghai Pulmonary Hospital, Professor Xiaorong Dong from Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, and Professor Lin Wu from Hunan Cancer Hospital published an investigator-initiated clinical trial (IIT) and translational research study on sintilimab plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) in Signal Transduction and Targeted Therapy, a Nature sub-journal (impact factor: 40.8). Amoy Diagnostics (300685.SZ), a Qiming Venture Partners portfolio company, participated deeply in this study, providing new insights for ES-SCLC treatment decisions through innovative research integrating blood and tumor microenvironment characteristics, demonstrating the important value of translational medical research.
Beyond demonstrating the favorable anti-tumor activity and safety of the combination regimen in ES-SCLC patients, the study performed multi-omics detection and analysis of pre-treatment tissue and blood samples, systematically mapping the local and systemic immune landscape of ES-SCLC for the first time, and successfully developing and validating a non-invasive prediction model based on peripheral blood proteomics to provide scientific evidence for precise patient stratification.
Product Launches
01/
Superhexa's Smart Glasses Brand Jiehuan Unveils Three New Products
Recently, Superhexa, a Qiming Venture Partners portfolio company, unveiled three new products under its smart glasses brand Jiehuan — a pure titanium Wellington style, a square cat-eye style, and a magnetic snap-on sunglasses style.
The pure titanium Wellington style carries forward the classic Wellington frame design born in the 1850s, crafted from rare titanium metal and warm-toned acetate. Weighing just 8.1 grams, the frame relieves pressure on the nose and ears, making it ideal for all-day wear. The square cat-eye style combines the boldness of classic square frames with the playfulness of cat-eye shapes, its face-lifting new design flattering facial contours. The magnetic snap-on sunglasses attach to Jiehuan's AI audio smart temples; they work as regular glasses — stylish, lightweight, and easy to wear — or as sunglasses, pulling double duty on fashion. The UV400 lenses block over 99% of ultraviolet rays, restoring crisp, clear vision.
02/
Yaoying Medical Officially Launches "AI Family Doctor" Agent
Achieving Full-Scenario Application of AI Agent + Real Doctor Dual-Track Service
Recently, Qiming Venture Partners portfolio company Yaoying Medical officially launched its "AI Family Doctor" agent. The product seamlessly connects with in-depth diagnosis and treatment by offline doctors, deeply integrating AI technology with professional medical resources to provide users with round-the-clock, high-quality healthcare experiences. It achieves full-scenario application of "AI Agent + Real Doctor Dual-Track Service," where the AI handles high-frequency, routine health consultations while doctors focus on critical decision-making and treatment planning.
The "AI Family Doctor" agent was jointly developed by Yaoying Medical and the Shanghai Artificial Intelligence Laboratory. Built on cutting-edge large language model technology, it provides users with full-scenario medical and health services including intelligent symptom checking, health consultations, chronic disease management, medication guidance, physical examination report interpretation, and lifestyle recommendations.
Additionally, the "AI Family Doctor" agent tailors health management plans for each family member based on their specific health records, examination history, and treatment history, adjusting as needed to provide long-term companionship.
Technology & Capabilities
01/
WeRide Enters Saudi Market
All Three Products Deployed
Recently, Qiming Venture Partners portfolio company WeRide (NASDAQ: WRD) announced its market expansion strategy for Saudi Arabia, marking a further expansion of the company's global commercial footprint. As its first step into the Saudi market, WeRide has tested and deployed autonomous driving products including Robotaxi, Robobus, and Robosweeper in key Saudi cities such as Riyadh and AlUla, laying the groundwork for subsequent large-scale commercial operations across the kingdom.
With the endorsement and support of Saudi Arabia's Transport General Authority (TGA), WeRide has already carried out extensive preparatory work in the kingdom. It will launch Robotaxi trial operations on the Uber platform in the coming months, with plans for comprehensive Robotaxi commercial operations in Saudi Arabia within 2025.
Meanwhile, WeRide has tested and deployed autonomous minibuses (Robobus) in multiple key areas across Saudi Arabia, including King Fahad Medical City, Aramco employee communities, AlUla, and The Ritz-Carlton, Riyadh, creating smooth transit connections linking campuses, scenic areas, and new urban districts.
Currently, WeRide's Robosweeper S1 autonomous sweeper has begun operations at King Fahad Medical City under Riyadh's Second Health Cluster — the first commercially operating autonomous sanitation project in Saudi Arabia and the broader Middle East.
02/ Shengshu Technology's Vidu Partners with CCTV Animation at the 21st China International Cartoon & Animation Festival
At the 21st China International Cartoon & Animation Festival, Qiming Venture Partners portfolio company Shengshu Technology's Vidu, in partnership with CCTV Animation, created an "AI + Animation IP Immersive Experience Zone" that became one of the most popular attractions at the event. This collaboration marks not only the first deep integration between a top-tier national animation IP and a world-leading AI video large-model platform, but also provides a replicable new template for AI + animation IP partnerships.
As a classic animated series produced by China Central Television, the 1999 version of Journey to the West is one of China's most enduring and influential national-level animation IPs. Vidu's AI technology elevates the IP from "visual symbol" to "interactive companion," using AI special effects templates to attract young users to fun, engaging interactions. This not only activates the fanbase of the Journey to the West master-disciple characters but also helps the brand penetrate broader emerging demographics, achieving full-spectrum user coverage and seamless cross-generational appeal.
03/ Speediance SPEEDIANCE Debuts at 2025 China International Sporting Goods Expo
Recently, Qiming Venture Partners portfolio company Speediance SPEEDIANCE unveiled its next-generation AI-powered intelligent fitness solutions — including the Gym Monster 2 and VeloNix — at the 2025 China International Sporting Goods Expo.
Notably, Speediance SPEEDIANCE introduced SPEEDIANCE One-Stop Scientific Fitness AI Agent — Speediance WELLNESS+. Leveraging AI large-model data combined with built-in intelligent algorithm systems, it enables full-chain digital empowerment including dynamic tracking, intelligent analysis, workout recommendations, and AI dialogue.
Speediance SPEEDIANCE integrates intelligent hardware, interactive software, and customized content services to create cross-scenario sports technology solutions for both home and commercial settings, delivering full-scenario, full-lifecycle intelligent fitness experiences.
04/ Dishangtie Releases Intercity Scenario Solution
Recently, Qiming Venture Partners portfolio company Dishangtie, a leading national new energy logistics vehicle intelligent operation service provider, released its Dishangtie Intercity Scenario Solution based on insights into intercity logistics scenarios. The company is working with ecosystem partners to jointly explore the path of electrification transformation and upgrading in intercity logistics.
The solution aims to address customer pain points in actual intercity scenarios, including range anxiety, cost challenges, and efficiency bottlenecks. It covers 3 major intercity scenarios, 5 core products, and 15 distinctive services, providing customers with a one-stop comprehensive solution through new energy logistics vehicles featuring efficient charging and ultra-long range, backed by comprehensive service systems.
05/ Gan & Lee Pharmaceuticals Supports 2025 Multi-National Diabetes Academic Conference
Recently, the 2025 Multi-National Diabetes Academic Conference, supported by Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH), was held in Beijing.
Professor Yiming Mu of the Chinese PLA General Hospital systematically reviewed the three major technical routes for current global insulin weekly formulations, with particular focus on the top three in development sequence worldwide: Novo Nordisk's Icodec, Eli Lilly and Company's Efsitora Alfa, and Gan & Lee Pharmaceuticals' GZR4. Notably, as the first Chinese insulin weekly formulation to enter Phase 3 clinical trials, Gan & Lee Pharmaceuticals' GZR4 ranks third globally in development progress. Multiple clinical studies have shown that GZR4's glucose-lowering effects steadily cover a full week, enabling once-weekly dosing. Compared to insulin degludec, GZR4 demonstrates superior glycemic efficacy and favorable safety characteristics.
06/
Peking University First Hospital Team Applies Cornerstone Robotics Surgery
Robotic System Completes Three Robot-Assisted Upper Urinary Tract Reconstruction Surgeries
Recently, a team led by Professor Li Xuesong, director of urology at Peking University First Hospital, used the Sentire® laparoscopic surgical robot from Cornerstone Robotics, a Qiming Venture Partners portfolio company, to successfully perform three innovative robot-assisted upper urinary tract reconstruction surgeries. The procedures demonstrated to attending experts the precise, personalized treatment outcomes made possible by combining specialized surgical expertise with domestically produced surgical robotics.
As a leader in China's innovative surgical robotics sector, Cornerstone Robotics has repeatedly assisted surgical expert teams in successfully tackling complex, high-difficulty operations, demonstrating reliable, efficient clinical utility and technological maturity.
07/ DeepWise Co-Developed Science Navigation Platform
Deployed at Major Universities and Leading Enterprises in Yibin, Sichuan
Following its launch at Peking University and Wuhan University, Science Navigator — a next-generation scientific research knowledge base and AI academic search platform co-developed by Qiming Venture Partners portfolio company DeepWise and AI for Science Institute, Beijing — has recently been deployed at major universities and leading enterprises across Yibin, Sichuan.
Science Navigator is committed to providing full-stack research assistance capabilities, systematically addressing critical pain points for researchers in literature screening, interdisciplinary knowledge discovery, and academic resource acquisition. It is particularly effective in tackling challenges such as information overload, cumbersome search processes, and time-consuming organization, helping researchers efficiently explore the latest developments at the academic frontier and devote more energy to genuine scientific breakthroughs. The platform is equipped with hundreds of leading algorithms and AI for Science large models independently developed by DeepWise, along with abundant computing power and flexible allocation capabilities, providing comprehensive support for various scientific computing scenarios.
08/
Chase Therapeutics' Next-Generation EGFR-TKI Zorifertinib
Included in Authoritative Clinical Treatment Guidelines
Recently, just one month after commercialization, zorifertinib — a next-generation EGFR-TKI from Qiming Venture Partners portfolio company Chase Therapeutics — was highlighted in the China Malignant Tumor Discipline Development Report (2024) published by the Chinese Anti-Cancer Association (CACA). The report identified zorifertinib as the first EGFR-TKI specifically designed and developed for central nervous system (CNS) metastasis patients, and the only next-generation TKI that is not a substrate for efflux proteins. It can cross the blood-brain barrier with 100% penetration, offering unique advantages in controlling intracranial lesions in non-small cell lung cancer (NSCLC) and providing a superior treatment option for CNS metastasis populations. Additionally, zorifertinib has been incorporated into the CSCO Guidelines for Primary NSCLC Diagnosis and Treatment (2025 Edition) as a Level I recommendation for EGFR-sensitive mutations with brain metastasis.
Yong Zhang, CEO of Chase Therapeutics, stated: "Chase Therapeutics has always adhered to the mission of 'developing innovative therapeutics for urgent clinical needs.' Just as zorifertinib's market launch has filled the unmet clinical gap for lung cancer patients with brain metastases, this also marks the entry of lung cancer brain metastasis treatment into an era of precision medicine. We look forward to improving drug accessibility to bring longer-term survival benefits to more patients and contribute to building a healthy China."
09/ Xinze Source Debuts at Brazil International Medical Equipment Exhibition
At Hospitalar 2025 — the largest and most influential medical industry exhibition in South America — Qiming Venture Partners portfolio company Xinze Source showcased its full-chain minimally invasive medical solutions, demonstrating to global customers the cutting-edge capabilities and craftsmanship of Chinese medical manufacturing.
Its precision components demonstrate medical quality built on micron-level craftsmanship. Core endoscope components such as snake bones, distal tip housings, and micro three-way valves employ high-precision CNC machining and medical-grade materials to ensure instrument flexibility and durability. Drive components including chains and braided meshes undergo over ten thousand fatigue tests to safeguard surgical stability.
Its endoscopic consumables and components achieve product innovation driven by clinical needs. Consumables such as stone retrieval baskets, snares, biopsy forceps, and hemostatic clips use biocompatible materials and minimally invasive designs to reduce patient trauma.
Its minimally invasive surgical instruments and components demonstrate the leap from "manufacturing" to "intelligent manufacturing." Instruments such as rongeurs, ultrasonic scalpels, and multi-fire forceps integrate ergonomic design with energy platform technology to enhance surgical precision and efficiency.
Its endoscope system solutions create a full-process service ecosystem. Full-chain component supply from the control section, light guide section, and insertion section helps customers rapidly respond to market demands.
Corporate Honors
Three Qiming Venture Partners Portfolio Company Leaders Selected for
MIT Technology Review's 35 Innovators Under 35 China List
Recently, the 2024 MIT Technology Review "35 Innovators Under 35" China list was officially announced. Three leaders from Qiming Venture Partners portfolio companies were selected: He Wang, assistant professor at Peking University and founder and chief technology officer of Galaxy Universal; Guohao Dai, associate professor at Shanghai Jiao Tong University and co-founder and chief scientist of Infinigence AI; and Xiangyu Zhang, chief scientist at StepFun. Yuan Qi, distinguished professor at Fudan University, dean of Shanghai Academy of AI for Science, and founder of Infinite Light Year, was invited to serve as a judge.
In 2017, DeepTech partnered with MIT Technology Review to formally bring the "35 Innovators Under 35" selection to China, focusing on identifying and cultivating young innovative talent in China's emerging technology sectors. Over eight years, the selection has developed a distinctive innovation ecosystem whose diversity has injected unique vitality into China's technological development — particularly in the AI sector, where its impact has been especially pronounced.
Previous Issues
Qiming Weekly | Qiming Venture Partners Portfolio Company Financing and Updates Vol. 18, 2025
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through mergers and acquisitions. Over 80 portfolio companies have become recognized unicorns or super-unicorns in their industries.
Among Qiming Venture Partners' portfolio companies, many have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.